Aquestive Therapeutics Inc
Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. It offers Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; EMYLIF, an oral film formulation of riluzole; ONDIF, an oral soluble film formulati… Read more
Aquestive Therapeutics Inc (AQST) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of December 2025: 0.252x
Based on the latest financial reports, Aquestive Therapeutics Inc (AQST) has a cash flow conversion efficiency ratio of 0.252x as of December 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-8.47 Million) by net assets ($-33.66 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Aquestive Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2005–2025)
This chart illustrates how Aquestive Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Aquestive Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Aquestive Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Monro Muffler Brake Inc
NASDAQ:MNRO
|
0.029x |
|
Shandong Oriental Ocean Sci-Tech Co Ltd
SHE:002086
|
-0.034x |
|
Zhejiang Vie Science & Technology Co Ltd
SHE:002590
|
0.045x |
|
Weihai Huadong Automation Co Ltd
SHE:002248
|
0.044x |
|
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
SHG:688505
|
0.019x |
|
Qingdao Eastsoft Communic Tech
SHE:300183
|
0.004x |
|
NAVIGATOR HLDGS LTD
F:1NV
|
N/A |
|
Sinclair, Inc.
F:HQ7
|
-0.130x |
Annual Cash Flow Conversion Efficiency for Aquestive Therapeutics Inc (2005–2025)
The table below shows the annual cash flow conversion efficiency of Aquestive Therapeutics Inc from 2005 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-33.66 Million | $-52.43 Million | 1.558x | +162.03% |
| 2024-12-31 | $-60.16 Million | $-35.76 Million | 0.594x | +892.16% |
| 2023-12-31 | $-106.49 Million | $-6.38 Million | 0.060x | -27.44% |
| 2022-12-31 | $-118.55 Million | $-9.79 Million | 0.083x | -79.44% |
| 2021-12-31 | $-82.13 Million | $-32.98 Million | 0.402x | -57.16% |
| 2020-12-31 | $-48.50 Million | $-45.46 Million | 0.937x | -90.47% |
| 2019-12-31 | $-6.12 Million | $-60.21 Million | 9.835x | +863.12% |
| 2018-12-31 | $10.08 Million | $-12.99 Million | -1.289x | -486.31% |
| 2017-12-31 | $-26.50 Million | $5.82 Million | -0.220x | -147.26% |
| 2016-12-31 | $-17.58 Million | $-8.18 Million | 0.465x | +226.96% |
| 2006-12-31 | $25.26 Million | $-9.26 Million | -0.366x | +73.28% |
| 2005-12-31 | $4.67 Million | $-6.39 Million | -1.371x | -- |